Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
Johanna Nystedt, Director, Blood Products at Finnish Red Cross Blood Service, reposted from Veripalvelu – Finnish Red Cross Blood Service on LinkedIn:
”It is not every day we can release a new blood product to meet an unmet medical need – Today was one of those days!!
Quoting Veripalvelu – Finnish Red Cross Blood Service‘s post:
”The blood service will begin supplying serum eye drops to patients suffering from severe dry eye syndrome and surface eye diseases!
Serum eye drops are made from serum separated from donated blood.
Serum contains natural nutrients, vitamins, and growth factors that support the healing of the eye’s surface tissues and relieve inflammation.
The eye drops are intended for patients with severe dry eye syndrome, for example due to eye diseases, rheumatic diseases, or rejection following stem cell transplantation.
Blood for serum donation is currently collected at the Blood Service office in Seinäjoki.
“Donors feel that they play an important role in helping patients, and they have been happy to be able to help them in a new way,” says Anu Keisala, Head of Blood Donation Operations.”

Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis